Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
- 31 August 1995
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 1 (4) , 168-172
- https://doi.org/10.1016/1078-1439(95)00058-5
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Prognostic Significance of Prostate Specific Antigen in Endocrine Treatment for Prostatic CancerJournal of Urology, 1990
- Prostate Specific Antigen for Assessing Response to Ketoconazole and Prednisone in Patients with Hormone Refractory Metastatic Prostate CancerJournal of Urology, 1990
- Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic CancerCancer, 1990
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. IV. Anti-Androgen Treated PatientsJournal of Urology, 1989
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.The Journal of cell biology, 1988
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985
- Interaction of estramustine phosphate with microtubule‐associated proteinsFEBS Letters, 1985